Lilly just wrote a $2.25B check to a 3-year-old company with ~150 people and no clinical asset. The dollar figure is the bait. Here is what is actually happening.
Profluent does not predict which existing proteins might work. It generates new ones that have never existed in nature, tests them in human cells, and feeds the results back into training. That…
